Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Linsitinib - Astellas

Drug Profile

Linsitinib - Astellas

Alternative Names: ASP-7487; OSI-906; OSI-906AA

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator OSI Pharmaceuticals
  • Developer Astellas Pharma; Multiple Myeloma Research Foundation
  • Class Cyclobutanes; Imidazoles; Pyrazines; Quinolines; Small molecules
  • Mechanism of Action Insulin receptor antagonists; Insulin-like growth factor-I receptor antagonists; Protein tyrosine kinase inhibitors; Receptor protein-tyrosine kinase antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Adrenocortical carcinoma
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Adrenocortical carcinoma; Liver cancer; Multiple myeloma; Non-small cell lung cancer; Ovarian cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 27 Dec 2017 Discontinued - Phase-I/II for Multiple myeloma (Combination therapy, Second-line therapy or greater) in Canada, USA (PO) (NCT01672736)
  • 27 Dec 2017 Astellas and MMRF terminates a phase I/II trial for Multiple myeloma in USA and Canada as the sponsor decided to stop further manufacture of the study drug (PO) (NCT01672736)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top